Summary & Overview
HCPCS Level II J9011: Injection, datopotamab deruxtecan-dlnk, 1 mg
HCPCS Level II code J9011 represents the injection of datopotamab deruxtecan-dlnk, billed per 1 mg unit. As an antineoplastic biologic administered by injection, this code is relevant for oncology infusion services nationwide and affects hospital outpatient departments, physician offices, and specialty infusion centers. It matters nationally because high-cost oncology injectables influence payer coverage policies, prior authorization workflows, and site-of-care decisions.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical service associated with J9011, the typical sites where the drug is administered, and the billing context for unit-based HCPCS reporting. The publication also summarizes benchmark considerations and policy updates that commonly affect HCPCS-level oncology codes, including unitization, billing at the drug acquisition cost, and common modifier use for administration or partial doses.
This summary prepares payers, billing professionals, and oncology practice managers to understand coding implications, reimbursement considerations, and the operational settings in which J9011 is most frequently used. Data not available in the input.
Billing Code Overview
HCPCS Level II code J9011 describes the injection of datopotamab deruxtecan-dlnk, 1 mg. This code represents a parenteral oncology medication administered by intravenous or other injection, typically used in an outpatient infusion or oncology clinic setting. The service type is injectable antineoplastic therapy and the typical site of service is hospital outpatient infusion center or physician office infusion suite.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with advanced or metastatic HER2-low or HER2-positive solid tumor (commonly breast cancer) presents to the oncology infusion center for systemic therapy. The oncologist has prescribed datopotamab deruxtecan-dlnk administered intravenously; billing uses J9011 charged per 1 mg vial. The typical workflow: pre-infusion nursing assessment (vital signs, review of allergies, baseline labs including CBC, CMP, and LFTs), verification of chemotherapy orders and weight-based dosing, pharmacy preparation and verification of J9011 under sterile compounding protocols, and administration via peripheral IV or implanted central venous access by an oncology infusion nurse. Observation for infusion-related reactions and post-infusion monitoring for potential adverse events (eg, neutropenia, interstitial lung disease/pneumonitis, hepatic toxicity) occur in the infusion suite. Documentation includes diagnosis, dose in mg, number of vials, lot number, route, start/stop times, site of service (typically outpatient hospital-based infusion center or physician office infusion suite), and any applicable modifier to reflect unusual circumstances (eg, discontinued service, drug wastage, patient tolerance issues). Typical payors involved include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for authorization, coverage, and payment adjudication.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |